Last reviewed · How we verify
NCT06553846
A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors
Phase 1 trial testing Lutetium [177Lu]-FAP-75 in Solid Tumors in 50 participants. Not yet recruiting.
18 February 2025
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 19 August 2024 |
| Primary completion | 18 February 2025 |
| Estimated completion | 18 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Lutetium [177Lu]-FAP-75 — full drug profile →
Conditions studied
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Fudan University
Who can join
Adults 18 to 80, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the safety, tolerability, initial efficacy, pharmacokinetic profile and radiation dosimetry of lutetium \[177Lu\]-FAP-75 in the treatment of patients with advanced solid tumors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.
Wu C, Kurniawan A, Ming Z, Antunes IF, et al · · 2026 · PMID 41622307 · DOI 10.1007/s00259-025-07711-3 -
Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors.
Wu X, Wang Y, Li Y, Hu W. · · 2025 · PMID 41425958 · DOI 10.3389/fnume.2025.1737443
Verify or expand the search:
- PubMed search for NCT06553846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumors
Currently open trials in the same condition.
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
- NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06553846 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 14 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06553846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing